Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DURECT CORPORATION

(DRRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

DURECT : Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Durect Corporation (Form 8-K)

06/16/2021 | 04:18pm EDT

CERTIFICATE OF AMENDMENT

OF THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

DURECT CORPORATION

The undersigned, James E. Brown, hereby certifies that:

1. He is the President and Chief Executive Officer of Durect Corporation, a Delaware corporation (the 'Corporation').

2. The original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on February 6, 1998 under the name 'Durect Therapeutics Corporation.'

3. Article Fourth, Paragraph (A) of the Corporation's Amended and Restated Certificate of Incorporation is amended and restated in its entirety to read as follows:

'(A) The Corporation is authorized to issue two classes of stock to be designated, respectively, 'Common Stock' and 'Preferred Stock.' The total number of shares which the Corporation is authorized to issue is Six Hundred and Ten Million (610,000,000) shares, each with a par value of $0.0001 per share. Six Hundred Million (600,000,000) shares shall be Common Stock and Ten Million (10,000,000) shares shall be Preferred Stock.'

4. This Certificate of Amendment of the Corporation's Amended and Restated Certificate of Incorporation has been duly adopted by this Corporation's board of directors and stockholders in accordance with the provisions of the Corporation's Amended and Restated Certificate of Incorporation and with Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment of Amended and Restated Certificate of Incorporation at Cupertino, California on June 15, 2021.

/s/ James E. Brown

James E. Brown

President and Chief Executive Officer

Disclaimer

Durect Corporation published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 20:17:09 UTC.


© Publicnow 2021
All news about DURECT CORPORATION
07/30DURECT : Management's Discussion and Analysis of Financial Condition and Results..
AQ
07/29DURECT : Q2 Earnings Snapshot
AQ
07/29DURECT CORPORATION ANNOUNCES SECOND : 30 p.m. ET (Form 8-K)
PU
07/29DURECT CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
07/29DURECT : Earnings Flash (DRRX) DURECT CORPORATION Reports Q2 Revenue $2.3M, vs. ..
MT
07/29DURECT CORPORATION : Announces Second Quarter 2021 Financial Results and Update ..
PR
07/22DURECT CORPORATION : to Announce Second Quarter 2021 Financial Results and Provi..
PR
07/14DURECT CORPORATION : to Present at the 2021 Epigenetic Therapeutic Targets Virtu..
PR
06/25DURECT : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submis..
AQ
06/23DURECT CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Financials (USD)
Sales 2021 8,56 M - -
Net income 2021 -40,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,69x
Yield 2021 -
Capitalization 321 M 321 M -
Capi. / Sales 2021 37,5x
Capi. / Sales 2022 19,0x
Nbr of Employees 81
Free-Float 98,6%
Chart DURECT CORPORATION
Duration : Period :
DURECT Corporation Technical Analysis Chart | DRRX | US2666051048 | MarketScreener
Technical analysis trends DURECT CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,41 $
Average target price 6,80 $
Spread / Average Target 382%
EPS Revisions
Managers and Directors
James E. Brown President, Chief Executive Officer & Director
Michael H. Arenberg Chief Financial Officer & Secretary
David R. Hoffmann Chairman
Wei Qi Lin Executive Vice President-Research & Development
David J. Ellis Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
DURECT CORPORATION-31.88%321
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-14.71%52 296